Get the Stockscreener App
9.43
7.64%
-0.78
Aligos Therapeutics Inc stock is traded at $9.43, with a volume of 114.23K.
It is down -7.64% in the last 24 hours and down -11.95% over the past month.
Aligos Therapeutics Inc is a clinical stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.
See More
Previous Close:
$10.21
Open:
$10.27
24h Volume:
114.23K
Relative Volume:
1.60
Market Cap:
$50.46M
Revenue:
$7.97M
Net Income/Loss:
$-75.74M
P/E Ratio:
-0.3883
EPS:
-24.2853
Net Cash Flow:
$-85.33M
1W Performance:
-6.36%
1M Performance:
-11.95%
6M Performance:
+136.34%
1Y Performance:
+36.87%
1-Day Range:
$9.28
$10.31
1-Week Range:
$9.28
$10.65
52-Week Range:
$3.76
$46.80
Aligos Therapeutics Inc Stock (ALGS) Company Profile
Name
Aligos Therapeutics Inc
Sector
Industry
Phone
(800) 466-6059
Address
ONE CORPORATE DR., 2ND FLOOR, SOUTH SAN FRANCISCO
Compare ALGS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALGS
Aligos Therapeutics Inc
|
9.43 | 70.97M | 7.97M | -75.74M | -85.33M | -24.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Aligos Therapeutics Inc Stock (ALGS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-18-25 | Resumed | H.C. Wainwright | Buy |
| Aug-19-24 | Initiated | H.C. Wainwright | Buy |
| Jan-06-23 | Upgrade | Jefferies | Hold → Buy |
| Jan-06-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-23-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jan-07-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Jan-06-22 | Downgrade | Jefferies | Buy → Hold |
| Sep-09-21 | Initiated | SVB Leerink | Outperform |
| May-17-21 | Resumed | Piper Sandler | Overweight |
| Nov-10-20 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-10-20 | Initiated | JP Morgan | Overweight |
| Nov-10-20 | Initiated | Jefferies | Buy |
| Nov-10-20 | Initiated | Piper Sandler | Overweight |
View All
Aligos Therapeutics Inc Stock (ALGS) Latest News
Why Aligos Therapeutics Inc. stock appeals to dividend seekersWeekly Profit Report & Weekly Breakout Opportunity Watchlist - newser.com
Will Aligos Therapeutics Inc. (5WK0) stock gain from green policiesEarnings Performance Report & Weekly Momentum Stock Picks - newser.com
Using data tools to time your Aligos Therapeutics Inc. exit2025 Fundamental Recap & AI Powered Trade Plan Recommendations - newser.com
Why Aligos Therapeutics Inc. is moving todayWeekly Trade Review & AI Enhanced Market Trend Forecasts - newser.com
How Aligos Therapeutics Inc. stock reacts to inflationary pressuresJuly 2025 Patterns & Weekly Top Gainers Trade List - newser.com
Is Aligos Therapeutics Inc. stock bottoming outMarket Sentiment Review & Verified Momentum Watchlists - newser.com
What momentum shifts mean for Aligos Therapeutics Inc.Gold Moves & Real-Time Chart Breakout Alerts - newser.com
Does Aligos Therapeutics Inc. qualify in momentum factor screeningTrade Analysis Report & Community Consensus Trade Signals - newser.com
Aligos Therapeutics (NASDAQ:ALGS) Earns "Sell (D-)" Rating from Weiss Ratings - MarketBeat
Published on: 2025-10-08 08:18:12 - earlytimes.in
Aligos Therapeutics Announces Eight Abstracts Accepted at The Liver Meeting® 2025 - Investing News Network
Aligos Therapeutics, Inc. Announces Eight Presentations at The Liver Meeting® 2025, Including Oral Presentation on Novel HBV Therapy - Quiver Quantitative
8 Abstracts Accepted — Aligos Presents Oral 96‑Week ALG-000184 HBV Data at The Liver Meeting 2025 - Stock Titan
Is Aligos Therapeutics Inc 5WK0 a good long term investmentStop Loss Placement Tips & High Profit Stock Alerts - earlytimes.in
Aligos Therapeutics reports new PD-1/PD-L1 interaction inhibitors - BioWorld MedTech
Is Aligos Therapeutics Inc. (5WK0) stock a fit for income portfoliosPortfolio Performance Report & Daily Volume Surge Trade Alerts - newser.com
How Aligos Therapeutics Inc. (5WK0) stock stacks up against competitorsJuly 2025 Final Week & Real-Time Stock Price Movement Reports - newser.com
How strong is Aligos Therapeutics Inc. stock balance sheetWeekly Trend Summary & Smart Money Movement Alerts - newser.com
How Aligos Therapeutics Inc. (5WK0) stock trades in high volatility2025 Winners & Losers & Weekly Consistent Profit Watchlists - newser.com
Aligos Therapeutics Inc. stock daily chart insightsJuly 2025 Trade Ideas & AI Enhanced Execution Alerts - newser.com
What to do if you’re stuck in Aligos Therapeutics Inc.July 2025 Sector Moves & Fast Gain Stock Tips - newser.com
D pipeline2025 Big Picture & Real-Time Price Movement Reports - newser.com
Aligos Therapeutics (NASDAQ:ALGS) Shares Up 5% – Should You Buy? - Defense World
What drives First Tellurium Corp G1J stock priceTake Profit Strategies & Minimal Capital Trading Tips - earlytimes.in
Aligos Therapeutics Inc Stock (ALGS) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):